NCT02027454 - Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions

Infection, Human Immunodeficiency Virus

Interventions

DRUG

GSK1265744

White to slightly colored film coated tablet with unit dose strength of 30 mg and dose level of 150mg (5 tablets of 3 mg) administered orally every 12hours for 3 doses.

DRUG

GSK1265744 matching placebo

GSK1265744 matching placebo tablets administered orally every 12hours for 3 doses (5 tablets per dose).

DRUG

Moxifloxacin

Dull red, oblong, convex film coated tablets with unit dose strength of 400 mg administered orally as a single dose.

Trial Locations (1)

66211

GSK Investigational Site, Overland Park